Company Analysis
Sign in

Ironwood Pharmaceuticals, Inc. (IRWD)

Nasdaq: IRWD · Pharmaceutical Preparations · Boston, MA · filing with the SEC since 2008
Full chart Alerts Compare
Grade5.0
◀ Past 4.2● Present 5.0▶ Future 5.9
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

48 patents granted to the 4 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Ironwood Pharmaceuticals, Inc.’s names, not what it holds today.

Patents granted
48
48 utility, 1976 to Dec 31, 2025
Granted in 2025
1
Against none in 2024 and 1 in 2023
Applications published
183
6 of them in 2025
Names they are printed under
4
its own name, a subsidiary
By yearGrantedApplications published
'11'12'13'14'15'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals2
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name4 counted
IRONWOOD PHARMACEUTICALS, INC. its own name
US, as the owner printed on each patent
46 granted
93 published
Ironwood Pharmaceuticals, Inc. its own name
named as the applicant on its applications, in US
0 granted
79 published
VectivBio AG a subsidiary
named as the applicant on its applications, in CH
0 granted
8 published
VectivBio AG a subsidiary
CH, as the owner printed on each patent
2 granted
3 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Nov 4, 202512,458,685Manufacture, formulation and dosing of apraglutidePharmaceuticalsVectivBio AG
Sep 26, 202311,766,470Manufacture, formulation and dosing of apraglutidePharmaceuticalsVectivBio AG
Jul 7, 202010,702,576Stable formulations of linaclotidePharmaceuticalsIRONWOOD PHARMACEUTICALS, INC.
Jun 9, 202010,675,325Stable formulations of linaclotidePharmaceuticalsIRONWOOD PHARMACEUTICALS, INC.
Apr 14, 202010,618,938Compositions for colon cleansing and the treatment of gastrointestinal disordersPharmaceuticalsIRONWOOD PHARMACEUTICALS, INC.
Apr 23, 201910,266,529Salts, co-crystals, and polymorphs of an anxiolytic compoundPharmaceuticalsIRONWOOD PHARMACEUTICALS, INC.
Jan 29, 201910,189,809SGC stimulatorsPharmaceuticalsIRONWOOD PHARMACEUTICALS, INC.
Jan 22, 201910,183,021sGC stimulatorsOrganic fine chemistryIRONWOOD PHARMACEUTICALS, INC.
Aug 14, 201810,047,095sGC stimulatorsPharmaceuticalsIRONWOOD PHARMACEUTICALS, INC.
May 15, 20189,969,742Imidazotriazinone compoundsOrganic fine chemistryIRONWOOD PHARMACEUTICALS, INC.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Oct 23, 20252025/0326798Synthetic Process for Production of Modified GCC Receptor AgonistsBiotechnologyIronwood Pharmaceuticals, Inc.
Oct 16, 20252025/0320250PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VISCERAL PAINPharmaceuticalsIronwood Pharmaceuticals, Inc.
Jun 19, 20252025/0197449Synthetic Process for Production of Modified GCC Receptor AgonistsBiotechnologyIronwood Pharmaceuticals, Inc.
Jun 12, 20252025/0186557MANUFACTURE, FORMULATION AND DOSING OF APRAGLUTIDEPharmaceuticalsVectivBio AG
Mar 6, 20252025/0073301Delayed Release Compositions of LinaclotidePharmaceuticalsIronwood Pharmaceuticals, Inc.
Feb 13, 20252025/0049893MANUFACTURE, FORMULATION AND DOSING OF APRAGLUTIDEPharmaceuticalsVectivBio AG
Oct 3, 20242024/0325500MANUFACTURE, FORMULATION AND DOSING OF APRAGLUTIDEPharmaceuticalsVectivBio AG
Aug 29, 20242024/0285730COMPOSITIONS AND METHODS FOR THE TREATMENT OF GRAFT VERSUS HOST DISEASEPharmaceuticalsVectivBio AG
Aug 1, 20242024/0252595MANUFACTURE, FORMULATION AND DOSING OF APRAGLUTIDEPharmaceuticalsVectivBio AG
Jun 20, 20242024/0199697Compositions for Colon Cleansing and the Treatment of Gastrointestinal DisordersPharmaceuticalsIronwood Pharmaceuticals, Inc.
What it applied for, 2024 to 2025: Pharmaceuticals 11 · Biotechnology 2.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton IRWD · research, not advice